Post-Market Clinical Follow-Up Study on the Rotational Stability of an Intraocular Lens After Cataract Surgery

NCT ID: NCT07099079

Last Updated: 2025-08-01

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 92 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2026-01-01
• Study Completion Date: 2026-11-30

Brief Summary

The goal of this post-market, prospective study at multiple clinics is to evaluate the rotational stability of the RayOne Model RAO800S non-toric monofocal intraocular lens with orientation marks in adult patients undergoing cataract surgery in both eyes. The main question it aims to answer is how stable the RayOne RAO800S lens is approximately 5 months (120 to 150 days) after surgery day. Participants are adults already scheduled to undergo cataract surgery as part of clinical routine. They will be asked to attend regular follow-up visits at the clinic, where eye images will be taken to assess the rotational stability of the implanted lens.

Detailed Description

This post-market clinical follow-up (PMCF) study is a prospective, multicenter investigation in European sites. It evaluates the rotational stability of the RayOne Model RAO800S, a non-toric monofocal intraocular lens with orientation marks, following bilateral implantation. Participants will be assessed approximately 5 months (120 to 150 days) post-operatively.

Conditions

IOL, Cataract

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Cataract patients

Adult patients scheduled for routine bilateral cataract surgery as part of their standard clinical care. All participants receive the RayOne RAO800S non-toric monofocal intraocular lens with orientation marks.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Male or female, 22 years or older at the pre-operative visit who have cataract in both eyes and who are eligible for phacoemulsification cataract surgery

2. Subjects who are projected to have best corrected distance visual acuity 0.20 logMAR (20/30) or better in both eyes after IOL implantation by investigator estimation

3. Clear intraocular media other than cataract

4. Contact lens wearers must demonstrate stability of biometry in both eyes

5. Have the capability to understand and sign an EC approved informed consent form and privacy authorization in accordance with local regulations

6. Female subjects must be 1-year postmenopausal, surgically sterilized, or if childbearing potential must use a stabilized and acceptable form of contraception from the beginning throughout the end of the study.

Stabilized and acceptable contraception methods include at least one of the following: intrauterine (intrauterine device) or hormonal (oral, injection, patch, implant, ring) for at least 3 months, barrier with spermicide (condom, diaphragm), or abstinence.

7. Have pre-existing corneal astigmatism not exceeding 1.25 D in both eyes as determined by keratometry

8. Dilated pupil size 5.5 mm or greater to allow visualization of the IOL orientation marks post-operatively in both eyes

Exclusion Criteria

1. Previous intraocular, corneal, or retinal detachment surgery, including corneal transplant, LASIK / LASEK / PRK, SMILE, astigmatic keratotomy and limbal relaxing incisions in any eye

2. Diagnosed degenerative visual disorders (e.g. macular degeneration, retinal detachment, proliferative diabetic retinopathy, or other retinal disorders) that are predicted to cause future acuity losses to a level of 0.20 logMAR (20/30) or worse

3. Significant anterior segment pathology that might increase intraoperative risk or compromise IOL stability (e.g. pseudoexfoliation syndrome, any iris pathology)

4. Subjects with conditions associated with increased risk of zonular rupture (that may affect post-operative centration or tilt of IOL) in any eye

5. Potentially occludable angle or ciliary body tumor, or other pathology that might increase risk to subject safety, based on adequate diagnostics e.g. gonioscopic, anterior OCT observation

6. Subjects reasonably expected to require secondary ocular surgical intervention or laser treatment (other than YAG capsulotomy)

7. Subjects with clinically significant corneal pathology, potentially affecting corneal topography

8. Subjects with traumatic cataract in any eye

9. Currently participating in a drug or device clinical trial, or having participated in such a trial within 30 days prior to the pre-operative visit

10. Subjects with any other serious ocular pathology (e.g. severe dry eye, history of intraocular inflammation, history of retinal surgery or retinal laser procedure) or underlying systemic medical condition (e.g., uncontrolled diabetes) or circumstance that, based on the investigator's judgment, poses a concern for the subjects' safety or could confound the results of the study

11. Clinically significant, uncontrolled glaucoma with expected negative impact on IOL Rotational Stability and / or visual acuity outcomes in one or both eyes

12. Use of medications known to interfere with visual performance, pupil dilation, or iris structure within 30 days of the pre-operative visit, at the discretion of the investigator

13. Pregnant or nursing females

14. Pre-operative corneal astigmatism above 1.25D as determined by keratometry

15. Irregular astigmatism in any eye

16. zonular instability;

17. need for iris manipulation;

18. capsular fibrosis or other opacity;

19. inability to fixate IOL in desired position

If the IOL has touched the eye, it should be noted if the reason for exclusion is related to the IOL itself and/or any (e.g. IOL or insertion device defect causing capsular damage, malfunction of insertion device).

If the IOL has touched the eye, the subject should be followed, for safety, until completion of the investigation.

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rayner Intraocular Lenses Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Pavel Stodulka, MD, PhD, FEBOS-CR

Role: CONTACT

stodulka@lasik.cz

+420 577 202 2

Other Identifiers

HRSS-2025-01

Identifier Type: -

Identifier Source: org_study_id